What is the regulatory status of Melanotan II?

Melanotan II regulatory status: Unapproved in the United States; WADA status not on prohibited list; research level mechanistic + off-label. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For healthspan and biological-age use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

What is the evidence base for Melanotan II?

Melanotan II's evidence base sits at mechanistic + off-label. The references on this page summarise 1 primary publication supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The longevity / hallmarks of aging interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

How should Melanotan II be stored and reconstituted?

Lyophilised Melanotan II stores at −20°C for 18–24 months. After reconstitution with bacteriostatic water, the solution holds at 4°C for 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Travel with cold packs in insulated containers; avoid prolonged exposure above 25°C. The standard reconstitution concentration is 1–2 mg/mL depending on the vial size.

How long until I see results from Melanotan II?

Acute effects from Melanotan II appear within hours of dosing for receptor-level changes. healthspan and biological-age endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

How does Melanotan II map to the hallmarks of aging?

Melanotan II's longevity relevance maps to specific hallmarks based on its mechanism. Non-selective melanocortin receptor agonist (MC1, MC3, MC4, MC5). MC1R drives pigmentation; MC4R drives appetite suppression and sexual response; MC3R/5R contribute to energy expenditure and sebaceous secretion. Cyclic structure resists enzymatic degradation. For users tracking healthspan-relevant biomarkers across cycles, the relevant endpoints are determined by which hallmark the compound primarily targets — telomere maintenance, senescence modulation, mitochondrial biogenesis, autophagy induction, inflammaging, or epigenetic clock effects. The framework above identifies the dominant contribution.

Home/ Compounds/ Melanotan II

Melanotan II

Longevity

For users tracking biological age and healthspan-relevant biomarkers, Melanotan II sits within a multi-component longevity framework spanning hallmarks-of-aging from cellular (telomere, senescence, mitochondrial) through integrative (inflammaging, nutrient sensing). The cyclic α-MSH analogue with MC4R activity — tanning effects plus the sexual-response effects that led to its derivative bremelanotide (PT-141). Cycle-based dosing over 8-12 weeks with pre-post biomarker tracking is the longevity-research convention.

Longevity / Hallmarks of Aging Applications

Mitochondrial BiogenesismTOR ModulationNutrient SensingNAD+ MetabolismHallmarks of Aging

Key Takeaways

Longevity lens: Melanotan II maps to specific hallmarks-of-aging endpoints rather than to acute clinical markers.
Mechanism: Non-selective melanocortin receptor agonist (MC1, MC3, MC4, MC5).
Healthspan biomarkers: epigenetic age, telomere length, inflammatory markers, metabolic flexibility - all tracked across pre-post cycles.
Longevity protocol: cycle-based 0.25-0.5 mg daily during loading, then 1-2x weekly dosing; 8-12 week cycles favoured over continuous administration.
Longevity stack partners: Epithalon, Thymalin, NAD+.

Longevity / Hallmarks of Aging Mechanism

For longevity-relevant evaluation, Melanotan II's mechanism is examined against the hallmarks of aging rather than against acute clinical endpoints. Non-selective melanocortin receptor agonist (MC1, MC3, MC4, MC5). MC1R drives pigmentation; MC4R drives appetite suppression and sexual response; MC3R/5R contribute to energy expenditure and sebaceous secretion. Cyclic structure resists enzymatic degradation. The subsections below address the hallmarks mapping, cellular reprogramming layer, healthspan markers, and dosing-pattern conventions in longevity research.

Mapping to the hallmarks of aging

Melanotan II's longevity relevance is best evaluated by mapping its mechanism to the hallmarks-of-aging framework. Non-selective melanocortin receptor agonist (MC1, MC3, MC4, MC5). MC1R drives pigmentation; MC4R drives appetite suppression and sexual response; MC3R/5R contribute to energy expenditure and sebaceous secretion. Cyclic structure resists enzymatic degradation. This places its dominant contribution in the integrative hallmarks (systemic and inflammatory) layer of the framework, with secondary effects on adjacent hallmarks that combine to produce the broader healthspan-relevant phenotype.

Cycle-based versus continuous dosing

Melanotan II's longevity protocol is compatible with either cycle-based or continuous dosing depending on the broader stack. The longevity-research convention favours pulsatile and periodic interventions over indefinite continuous administration, on the principle that hormetic stimulation outperforms sustained agonism for systems-biology-relevant endpoints.

Healthspan markers and biological age

For users measuring epigenetic age, telomere length, or composite biological-age markers (Horvath, PhenoAge, GrimAge) before and after Melanotan II cycles, the question is whether the intervention measurably moves these markers. Current evidence varies by compound but the framework for evaluation is shared: paired pre-post measurement with appropriate inter-test interval.

Longevity / Hallmarks of Aging Applications

NAD+ Metabolism

For nad+ metabolism as a longevity-relevant endpoint, Melanotan II is typically run in cycle-based protocols with paired pre-post biomarker measurement. Epigenetic age tracking, telomere length, and inflammatory panels are the standard outcome measures.

Nutrient Sensing

Nutrient Sensing maps to one of the hallmarks of aging and is one of the dimensions on which Melanotan II is evaluated in the longevity literature. Effect size on biomarkers varies across studies; the consistent finding is direction-of-effect rather than dramatic magnitude.

Telomere Support

Melanotan II's contribution to telomere support as a longevity dimension is incremental rather than dramatic, consistent with the broader picture of healthspan-relevant peptides. The compound is best understood as one layer in a multi-component longevity protocol.

Inflammaging

For inflammaging as a longevity-relevant endpoint, Melanotan II is typically run in cycle-based protocols with paired pre-post biomarker measurement. Epigenetic age tracking, telomere length, and inflammatory panels are the standard outcome measures.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	0.25-0.5 mg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	1.25-0.5 mg	4–6 weeks initial cycle
Longevity focus	SubQ	0.25-0.5 mg	Daily during loading, then 1-2x weekly
Maintenance phase	SubQ	1.25-0.5 mg	Ongoing with periodic pauses

Dose timing for Melanotan II is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

Melanotan II stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from longevity researchers.

Melanotan II + Epithalon: Identified by Khavinson in St. Pairs naturally with Melanotan II's mechanism in longevity / hallmarks of aging protocols.
Melanotan II + Thymalin: Influences T-cell maturation and immune function. Pairs naturally with Melanotan II's mechanism in longevity / hallmarks of aging protocols.
Melanotan II + NAD+: Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle. Pairs naturally with Melanotan II's mechanism in longevity / hallmarks of aging protocols.
Melanotan II + MOTS-c: Translocates to the nucleus under metabolic stress and activates AMPK signalling. Pairs naturally with Melanotan II's mechanism in longevity / hallmarks of aging protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Unapproved Research: Mechanistic + off-label

Nausea (especially early), spontaneous erections in men, marked appetite suppression, hyperpigmentation. Watch new moles closely. Avoid in melanoma history.

Lens-specific safety considerations for longevity / hallmarks of aging use of Melanotan II: Nausea (especially early), spontaneous erections in men, marked appetite suppression, hyperpigmentation. Watch new moles closely. Avoid in melanoma history. Additional longevity / hallmarks of aging monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Melanotan analogues and melanocortin receptor pharmacology

PMID 1429592

Melanotan II vs Related Peptides

Compound	Profile	Onset	Best For
Melanotan II	Cyclic α-MSH analogue	~30 min	Longevity
Epithalon	Pineal-derived tetrapeptide	Very short (minutes)	A pineal-derived tetrapeptide best known for telomerase upregulation and pineal-gland melatonin restoration in long-running rodent and human studies
Thymalin	Thymic polypeptide extract	Variable	A complex of low-molecular-weight thymic polypeptides used in Russian clinical research for decades — immunomodulation, anti-aging, and supportive care in chronic disease
MOTS-c	Mitochondrially-encoded peptide	Hours; tissue-distributed	A 16-amino-acid peptide encoded within mitochondrial DNA — discovered in 2015 and shown to regulate metabolic homeostasis, AMPK signalling, and insulin sensitivity
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression

Frequently Asked Questions

Does Melanotan II interact with rapamycin, metformin, or other longevity stacks?

Most peptide compounds are compatible with the standard longevity small-molecule stack (rapamycin, metformin, NAD precursors, senolytics in pulsed protocols). Interactions where present are typically additive rather than competitive. Verify case-specifically with a longevity-informed clinician.

What are the long-term safety considerations?

Long-term safety data for most peptide compounds is limited to a small number of well-studied molecules with multi-decade clinical observation. For most others, the long-term framework relies on mechanism-based risk assessment plus accumulating clinical experience. Cycle-based dosing and periodic re-evaluation are appropriate for compounds without 10+ year human safety data.

Best stack pairing for longevity?

Layered protocols cover multiple hallmarks of aging simultaneously: pineal/telomere (epithalon), thymic/immune (thymalin), mitochondrial (MOTS-c, NAD+), ECM and gene expression (GHK-Cu), and metabolic flexibility (metformin-class or GLP-1-class as appropriate). Melanotan II contributes to its specific hallmark layer in this multi-component framework.

When in life should I start Melanotan II?

Most longevity-relevant peptides have evidence bases centred on mid-life and later. Earlier use is theoretically reasonable for users with documented age-related markers (elevated inflammation, accelerated epigenetic age) or for compounds whose mechanism is preventative. Below age 35 the benefit for most longevity peptides is theoretical and warrants compound-specific consideration.

What is the mechanism of action of Melanotan II?

Non-selective melanocortin receptor agonist (MC1, MC3, MC4, MC5). MC1R drives pigmentation; MC4R drives appetite suppression and sexual response; MC3R/5R contribute to energy expenditure and sebaceous secretion. Cyclic structure resists enzymatic degradation. For healthspan and biological-age applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: Non-selective melanocortin receptor agonist (MC1, MC3, MC4, MC5). The longevity / hallmarks of aging interpretation focuses on the pathway-level detail rather than on any single high-level summary.

What are the safety considerations for Melanotan II?

Nausea (especially early), spontaneous erections in men, marked appetite suppression, hyperpigmentation. Watch new moles closely. Avoid in melanoma history. For healthspan and biological-age use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. Melanotan II's ~30 min pharmacokinetic profile and subq/intranasal administration route influence the side-effect profile in predictable ways.

Clinical Protocol

Start a Melanotan II Protocol

Alukard provides physician-supervised longevity protocols with GMP-certified Melanotan II and GMP-certified compounds with biological age testing and healthspan markers.

Get Protocol

Quick Facts

Molecular weight: 1024 Da
Sequence length: 7 aa
Half-life: ~30 min
WADA: Not on prohibited list
FDA: Unapproved
Research: Mechanistic + off-label

Stack Partners

Epithalon

Thymalin

NAD+

MOTS-c

GHK-Cu

Research Note

All longevity / hallmarks of aging applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Melanotan II unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised longevity protocols

Start Your Longevity / Hallmarks of Aging Protocol for Melanotan II

Alukard provides physician-supervised longevity protocols with GMP-certified compounds with biological age testing and healthspan markers.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised